3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Classical hematology
1
Conditions
Neutropenia
1
Neoplasms
1
Hematologic Neoplasms
1
Fever
1
Febrile Neutropenia
1
Interventions
Epoetin Alfa
25
Darbepoetin alfa
17
apixaban
9
Rivaroxaban
9
Dalteparin
7
Heparin, Low-Molecular-Weight
6
Surveys and Questionnaires
5
Meropenem
5
fludarabine phosphate
4
Vancomycin
4
Tinzaparin
4
Enoxaparin
4
Cyclosporine
4
Cefepime
4
ferric carboxymaltose
3
edoxaban
3
Whole-Body Irradiation
3
Peripheral Blood Stem Cell Transplantation
3
Mycophenolic Acid
3
Ceftazidime
3
Carboplatin
3
Busulfan
3
Antilymphocyte Serum
3
Amikacin
3
romiplostim
2
peginesatide
2
hematide
2
fludarabine
2
epoetin beta
2
bemiparin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
Cilastatin, Imipenem Drug Combination
×
Classical hematology
×
Clear all
NCT02149329
2019-09-25
SHORT
Amsterdam UMC, location VUmc
Phase 4
Completed
276 enrolled